Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy — StellaPhase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(38 sites)
United States
Univ of Alabama/Birmingham, Birmingham, Alabama Arizona Kidney Disease & Hypertension Centers (AKDHC), Glendale, Arizona The Medical Research Group, Inc., Fresno, California UCI Health-UCI Medical Center, Orange, California Loma Linda University, San Bernardino, California Last updated February 2026